Compare Honeywell International Inc (HON) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Honeywell International Inc trades at $230.29 (market cap $71.66B), while State Street SPDR S&P Biotech ETF trades at $154.21. The key difference: Honeywell International Inc pays a 4.21% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Honeywell International Inc nearer its low. Which is the better fit depends on your goals.
| HON | XBI | |
|---|---|---|
Market Cap | $71.66B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $248.04 | $164.28 |
52-Week Low | $188.14 | $85.16 |
Enterprise Value | $96.01B | — |
Dividend Yield | 4.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $225.78, up 0.34% with a bullish technical signal and strong institutional support. The company maintains solid fundamentals with a 10.89% net margin and 26.41% ROE, though recent earnings show mixed trends with Q1 2026 beating expectations but full-year 2026 guidance indicating potential decline. Recent developments include the completion of a £1.325 billion acquisition and a 2:1 reverse stock split.
The outlook remains positive with analyst consensus favoring Buy ratings (65.52%) and a $368.55 price target representing significant upside. Key risks include execution challenges post-spinoffs and margin pressure, while opportunities lie in automation growth and strategic acquisitions. The stock presents a balanced risk-reward profile for long-term investors.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
